These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16358950)

  • 1. Diabetic nephropathy and cardiovascular diseases.
    Czekalski S
    Rocz Akad Med Bialymst; 2005; 50():122-5. PubMed ID: 16358950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R; Yeung JM; Manning G
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Microalbuminuria--a risk factor for diabetic nephropathy and cardiovascular disease].
    Pontuch P
    Vnitr Lek; 2001 May; 47(5):307-10. PubMed ID: 11395874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management].
    Czekalski S
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():65-9. PubMed ID: 15669203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is microalbuminuria, an early marker of clinical nephropathy, also a cardiovascular risk factor?].
    Raynaud E; Brun JF; Fédou C; Puech-Cathala AM; Pérez-Martin A; Orsetti A
    Ann Biol Clin (Paris); 1998; 56(6):671-9. PubMed ID: 9853026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
    Navarro JF; Mora C; Gómez M; Muros M; López-Aguilar C; García J
    Nephrol Dial Transplant; 2008 Mar; 23(3):919-26. PubMed ID: 17911088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microalbuminuria: theoretical bases and new applications].
    Airoldi G; Campanini M
    Recenti Prog Med; 1993 Mar; 84(3):210-24. PubMed ID: 8465103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microalbuminuria, endothelial dysfunction and cardiovascular risk.
    Feldt-Rasmussen B
    Diabetes Metab; 2000 Jul; 26 Suppl 4():64-6. PubMed ID: 10922975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.
    Ogawa Y; Goto T; Tamasawa N; Matsui J; Tando Y; Sugimoto K; Tomotsune K; Kimura M; Yasujima M; Suda T
    Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes.
    Naidoo DP
    Cardiovasc J S Afr; 2002; 13(4):194-9. PubMed ID: 12389063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing microalbuminuria in patients with type 2 diabetes.
    Jermendy G; Ruggenenti P
    Diabetes Metab Res Rev; 2007 Feb; 23(2):100-10. PubMed ID: 17094161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic nephropathy.
    Ritz E
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetes mellitus and microalbuminuria].
    Krusová D
    Vnitr Lek; 2007 Dec; 53(12):1310-8. PubMed ID: 18357867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus.
    Araki S; Haneda M; Koya D; Kashiwagi A; Uzu T; Kikkawa R
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S54-8. PubMed ID: 18947896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type 2 diabetic nephropathy: clinical course and prevention proposals 2004].
    Tarchini R; Bottini E; Botti P; Marseglia CD; Talassi E; Baraldi O; Lambertini D; Gaetti L; Bellomi A
    G Ital Nefrol; 2005; 22 Suppl 31():S15-9. PubMed ID: 15786392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.